Pfizer on Thursday said it submitted a request to U.S. drug regulators to expand the authorization for its COVID-19 vaccine to children between the ages of 5 and 11.
The U.S.-based pharmaceutical company and its German partner BioNTech sent the request to the Food and Drug Administration (FDA) about a week after submitting data they said showed the vaccine triggered antibody responses in children in a Phase 2/3 clinical trial. Full results for the trial, which is run by the companies, have not yet been released.-- More...